HUP9903249A2 - VX478, Zidovudin, FTC és/vagy 3TC kombinációjának alkalmazása HIV kezelésére - Google Patents

VX478, Zidovudin, FTC és/vagy 3TC kombinációjának alkalmazása HIV kezelésére

Info

Publication number
HUP9903249A2
HUP9903249A2 HU9903249A HUP9903249A HUP9903249A2 HU P9903249 A2 HUP9903249 A2 HU P9903249A2 HU 9903249 A HU9903249 A HU 9903249A HU P9903249 A HUP9903249 A HU P9903249A HU P9903249 A2 HUP9903249 A2 HU P9903249A2
Authority
HU
Hungary
Prior art keywords
hiv
treatment
amino
combinations
ftc
Prior art date
Application number
HU9903249A
Other languages
English (en)
Inventor
David Walter Barry
Martha Heider St.Clair
Original Assignee
Glaxo Group Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614022.3A external-priority patent/GB9614022D0/en
Application filed by Glaxo Group Ltd. filed Critical Glaxo Group Ltd.
Publication of HUP9903249A2 publication Critical patent/HUP9903249A2/hu
Publication of HUP9903249A3 publication Critical patent/HUP9903249A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

A találmány tárgya anti-HIV hatású gyógyászati kombinációk, amelyek3S-[3R*(1R*,2S*)]-[3-[[(4-amino-fenil)-szulfonil](2-metil-propil)-amino]-2-hidroxi-1-fenil-metil)-propil]-karbaminsav-tetrahidro-3-furanil-észterből (141W94), 3'-azido-3'-dezoxi-timidinból (zidu-vidin)és (2R, cisz)-4-amino-1-(2-hidroxi-metil-1,3-oxatiolán-5-il)-(1H)-pirimidin-2-on-ból (3TC, lamivudin) (vagy a lamivudin analógiájára(2R,cisz)-4-amino-5-fluor-1-(2-hidroxi-metil-1,3-oxatiolán-5-il)-(1H)-pirimidin-2-onból (FTC) állnak. A jelen találmány kiterjed ezenkombinációkat tartalmazó gyógyászati készítményekre és alkalmazásukraHIV-fertőzés kezelésére, ideértve a nukleozid és/vagy nem-nukleozidinhibitorokkal szembeni rezisztenciát mutató HIV-mutánsok általokozott fertőzések kezelését is. Ó
HU9903249A 1996-06-25 1997-06-23 Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv HUP9903249A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2054396P 1996-06-25 1996-06-25
US2102796P 1996-07-02 1996-07-02
GBGB9614022.3A GB9614022D0 (en) 1996-07-04 1996-07-04 Antiviral therapeutic combinations
PCT/EP1997/003247 WO1997049411A1 (en) 1996-06-25 1997-06-23 Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv

Publications (2)

Publication Number Publication Date
HUP9903249A2 true HUP9903249A2 (hu) 2000-10-28
HUP9903249A3 HUP9903249A3 (en) 2001-04-28

Family

ID=27268358

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903249A HUP9903249A3 (en) 1996-06-25 1997-06-23 Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv

Country Status (26)

Country Link
US (1) US6544961B1 (hu)
EP (1) EP0938321B1 (hu)
JP (1) JP2000515852A (hu)
KR (1) KR20000022226A (hu)
CN (1) CN1228026A (hu)
AP (1) AP9801419A0 (hu)
AT (1) ATE257708T1 (hu)
AU (1) AU727983B2 (hu)
BR (1) BR9709939A (hu)
CA (1) CA2258956A1 (hu)
CO (1) CO4900074A1 (hu)
CZ (1) CZ429498A3 (hu)
DE (1) DE69727240T2 (hu)
EA (1) EA001517B1 (hu)
ES (1) ES2213217T3 (hu)
HU (1) HUP9903249A3 (hu)
ID (1) ID19490A (hu)
IL (1) IL127351A0 (hu)
IS (1) IS4915A (hu)
NO (1) NO986034L (hu)
NZ (1) NZ333099A (hu)
PL (1) PL330747A1 (hu)
TR (1) TR199802704T2 (hu)
TW (1) TW469132B (hu)
WO (1) WO1997049411A1 (hu)
YU (1) YU58398A (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
NZ554779A (en) * 2005-02-01 2011-02-25 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts
ES2279707B1 (es) * 2005-11-10 2008-06-01 Combino Pharm, S.L. Formulaciones orales que comprenden 3'-azidonucleosidos.
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
US20110052580A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
MX367937B (es) * 2010-01-27 2019-09-12 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
SK279262B6 (sk) 1991-05-16 1998-08-05 Glaxo Group Limited Protivírusová zmes, farmaceutický prostriedok s je
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
DK0656887T3 (da) 1992-08-25 1999-07-05 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
GB9503850D0 (en) 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
TW536403B (en) 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy

Also Published As

Publication number Publication date
HUP9903249A3 (en) 2001-04-28
ES2213217T3 (es) 2004-08-16
CA2258956A1 (en) 1997-12-31
US6544961B1 (en) 2003-04-08
ID19490A (id) 1998-07-16
DE69727240T2 (de) 2004-11-25
AU727983B2 (en) 2001-01-04
KR20000022226A (ko) 2000-04-25
CO4900074A1 (es) 2000-03-27
ATE257708T1 (de) 2004-01-15
EA001517B1 (ru) 2001-04-23
BR9709939A (pt) 1999-08-10
NO986034D0 (no) 1998-12-22
YU58398A (en) 1999-11-22
WO1997049411A1 (en) 1997-12-31
NZ333099A (en) 2000-06-23
AP9801419A0 (en) 1998-12-31
CZ429498A3 (cs) 1999-06-16
EP0938321A1 (en) 1999-09-01
NO986034L (no) 1999-02-23
IS4915A (is) 1998-11-30
AU3262797A (en) 1998-01-14
JP2000515852A (ja) 2000-11-28
TW469132B (en) 2001-12-21
EP0938321B1 (en) 2004-01-14
IL127351A0 (en) 1999-10-28
TR199802704T2 (xx) 1999-03-22
PL330747A1 (en) 1999-05-24
CN1228026A (zh) 1999-09-08
EA199801045A1 (ru) 1999-08-26
DE69727240D1 (de) 2004-02-19

Similar Documents

Publication Publication Date Title
HUP9903249A2 (hu) VX478, Zidovudin, FTC és/vagy 3TC kombinációjának alkalmazása HIV kezelésére
MY115461A (en) Synergistic combinations of zidovudine, 1592u89 and 3tc
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
PL408254A1 (pl) Kompozycje i i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej
TNSN92070A1 (fr) Les analogues du necleoside de 13-oxathiolane
TNSN91029A1 (fr) Les analogues du nucleoside de 1,3-oxathiolane
BR0311154A (pt) Composição para melhorar o melasma e composição para reduzir a opacidade da pele
HUP0002982A2 (hu) Lamivudint tartalmazó folyékony gyógyszerkészítmény
AR023661A1 (es) Combinaciones antivirales
YU58498A (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
AR007616A1 (es) Combinaciones antivirales
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
WO2001030329A3 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
AR007615A1 (es) Combinaciones antivirales, formulaciones conteniendo las mismas, uso de los mismos en la manufactura de medicamentos y un articulo que los contiene.
AR043332A1 (es) Composiciones y metodos para terapia antiviral
WO2000018384A3 (en) Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
TH34798A (th) การรวมสารต้านไวรัส
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral
Sundari et al. Primary Systemic Amyloidosis–A Great Mimicker
TH34652A (th) การรวมสารต้านไวรัส